8-K: Accuray Fortifies Capital Structure with Major Debt Refinancing and Convertible Notes Exchange; Appoints New Board Director

Accuray Incorporated announced a comprehensive financial restructuring, including the exchange of $82 million in convertible notes, a new $190 million senior secured credit facility, and the appointment of Steven F. Mayer to its Board of Directors.

Summary

• Accuray Incorporated has entered into privately-negotiated exchange agreements to exchange approximately $82.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2026.
• The exchange consideration includes 8,881,579 shares of common stock and an aggregate cash payment of approximately $68.6 million.
• The exchange is expected to be consummated on June 11, 2025, which will leave approximately $18.0 million of the 2026 Notes outstanding.
• The company secured a new senior secured credit agreement with TCW Asset Management Company LLC, providing $150 million in new five-year term loan facilities, a $20 million delayed draw term loan facility, and a $20 million revolving credit facility, all maturing on June 6, 2030.
• Proceeds from the term loan facilities will be used to fully refinance existing senior secured indebtedness and to consummate the convertible notes exchange; the delayed draw facility may be used for future repurchases of 2026 Notes, and the revolving credit facility for general working capital and corporate purposes.
• Interest on the new facilities is payable at a term SOFR-based rate (subject to a 2.00% per annum floor) plus an 8.50% applicable margin, or a base rate (subject to a 3.00% per annum floor) plus a 7.50% applicable margin, with up to 6.00% per annum of the base rate interest potentially paid in kind (PIK) subject to a margin increase.
• The new financing agreement contains customary restrictions and covenants, including requirements for Total Leverage Ratio, Fixed Charge Coverage Ratio, and Liquidity thresholds.
• Concurrently, Accuray issued warrants to lenders: 17,180,710 Premium Warrants (exercisable after six months and one day, expiring June 6, 2032, with an exercise price of $1.68 per share) and 6,247,531 Penny Warrants (immediately exercisable, expiring June 6, 2032, with an exercise price of $0.01 per share).
• Additional DDTL Premium and Penny Warrants will be issued upon drawing on the Delayed Draw Facility, and all warrants include anti-dilution protection provisions.
• The company terminated its existing senior secured credit agreement with Silicon Valley Bank, dated May 6, 2021.
• Steven F. Mayer, designated by TCW, was appointed to Accuray's Board of Directors as a Class III director, with his term expiring at the 2027 annual meeting of stockholders; TCW also has the right to designate two non-voting board observers.

Sentiment

Score: 6

Explanation: The announcement reflects a necessary and successful financial restructuring, addressing upcoming debt maturities and enhancing liquidity. However, the high cost of new debt, significant potential dilution from warrants, and increased governance influence by the lender introduce notable financial and operational considerations. The overall sentiment is cautiously positive, as the company has secured its financial footing but at a cost.

Positives

• Successful refinancing of existing senior secured indebtedness and a significant portion of convertible notes, addressing upcoming maturities and improving the company's capital structure.
• New credit facilities provide $190 million in total capacity ($150M term loan, $20M delayed draw, $20M revolving credit), enhancing liquidity and operational flexibility.
• The new financing has a five-year maturity (June 6, 2030), providing longer-term stability compared to the 2026 notes.
• Appointment of Steven F. Mayer to the Board brings extensive experience in corporate governance, medical technology, and private equity, which could be a valuable asset.
• The company's expanded solution portfolio is stated to be the strongest in its history, positioning it for long-term growth.

Negatives

• Issuance of 8,881,579 shares of common stock as part of the convertible notes exchange will result in shareholder dilution.
• Issuance of 17,180,710 Premium Warrants and 6,247,531 Penny Warrants (plus potential DDTL warrants) to lenders represents significant potential future dilution upon exercise.
• The interest rates on the new credit facilities (SOFR + 8.50% or Base Rate + 7.50%) appear to be high, indicating a higher cost of debt.
• The ability to pay interest in kind (PIK) on term loans, while preserving cash, will increase the principal balance and overall debt burden.
• The new credit agreement includes restrictive covenants (Total Leverage Ratio, Fixed Charge Coverage Ratio, Liquidity thresholds) that could limit the company's operational and financial flexibility.
• TCW, as a significant lender and warrant holder, gains governance influence through a board director and two non-voting observers, which could impact independent board decision-making.

Risks

• Dilution Risk: Significant potential dilution from the issuance of common stock for convertible notes exchange and the various warrants (Premium, Penny, DDTL).
• Financial Covenants: Failure to comply with Total Leverage Ratio, Fixed Charge Coverage Ratio, or Liquidity thresholds could trigger a default under the new Financing Agreement.
• High Cost of Debt: The high interest rates (SOFR + 8.50% or Base Rate + 7.50%) and potential for PIK interest increase the financial burden and could impact profitability.
• Market Price Volatility: Anti-dilution provisions in warrants are triggered if stock is sold below $1.00 or $1.25, indicating potential concern about future stock price performance.
• Integration Risk: The company's ability to successfully execute on its long-term growth strategies and invest in key business areas depends on effective utilization of the new capital structure.
• Regulatory Compliance: Ongoing compliance with SEC filing requirements and Nasdaq listing rules, especially concerning shareholder approval for warrant exercises if certain thresholds are met.

Future Outlook

The new capital structure is expected to enhance liquidity and provide greater operational flexibility, positioning Accuray well to execute on its long-term growth strategies and further invest in key business areas, including transforming radiation therapy care and creating long-term shareholder value. The Delayed Draw Facility proceeds may be used to fund future repurchases of outstanding 2026 Notes.

Management Comments

• "I am thrilled to have Steven join the Board. He brings valuable experience that will be an asset to the company and I look forward to working with him, and my fellow directors, on the achievement of two key strategic priorities – transforming radiation therapy care and creating long term shareholder value." Suzanne Winter, President and CEO of Accuray.
• "Our expanded solution portfolio is the strongest in our company’s history." Suzanne Winter, President and CEO of Accuray.
• "I am very pleased with the new financing agreement, which we believe positions Accuray well to execute on the long term growth strategies we have laid out, and helps provide the necessary resources to further invest in key business areas." Suzanne Winter, President and CEO of Accuray.
• "The new capital structure is expected to enhance liquidity and provide greater operational flexibility moving forward." Suzanne Winter, President and CEO of Accuray.

Industry Context

This announcement reflects a strategic move by Accuray, a medical technology company specializing in radiation therapy, to optimize its capital structure. In the broader medical technology and healthcare sectors, companies often seek to refinance debt to extend maturities, reduce interest costs, or gain financial flexibility for R&D, M&A, or market expansion. The involvement of a global asset manager like TCW suggests a sophisticated approach to securing financing, potentially indicating a challenging market for traditional bank lending or a preference for private credit solutions. The focus on "transforming radiation therapy care" aligns with ongoing innovation trends in oncology and precision medicine.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experience significant dilution from the issuance of common stock for convertible notes exchange and potential future dilution from warrants. The refinancing aims to stabilize the company's financial position, which could be positive long-term, but the immediate impact is dilution and a higher cost of debt.
• Creditors (2026 Notes Holders): A significant portion of 2026 Notes holders participated in an exchange for a mix of cash and equity, reducing the company's near-term debt obligations. Remaining 2026 Notes holders face a smaller outstanding principal amount.
• New Lenders (TCW): Gain a senior secured position with first-priority liens on company assets, high interest rates, and equity upside through warrants, along with significant governance influence.
• Employees: Financial stability from the refinancing could provide a more secure operating environment.
• Customers/Suppliers: Improved financial health may lead to more stable operations and continued investment in products and services.

Next Steps

• Consummation of the convertible notes exchange on June 11, 2025.
• Company subsidiaries to grant first-priority liens on substantially all their assets within 90 days of the Financing Agreement closing date.
• Filing of the full Financing Agreement as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2025.
• Potential future repurchases of outstanding 2026 Notes using proceeds from the Delayed Draw Facility.
• Company to file a registration statement (Form S-3 or S-1 Shelf) within 60 calendar days of the Eligible Exercise Date for the resale of warrant shares.
• Company to maintain the Shelf registration statement continuously effective until all warrant shares are sold or can be sold under Rule 144 without volume/manner of sale requirements.
• Company to convert Form S-1 Shelf to Form S-3 Shelf as soon as eligible.

Key Dates

Recommendation

Keywords

Accuray, ARAY, SEC Filing, 8-K, Convertible Notes, Debt Refinancing, Senior Secured Credit, Term Loan, Revolving Credit, Warrants, Equity Dilution, Corporate Governance, Board Appointment, TCW Asset Management, Financial Restructuring, Capital Structure, Radiation Therapy, Medical Technology